AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03379714 — intervention group
Intervention type: DEVICE
Intervention: WEB aneurysm embolization system
Description: The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.
Study NCT03226457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg
Description: Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks
Study NCT03226457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
Study NCT03226457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frusemide
Description: Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.
Study NCT04064554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCG vaccination with MicronJet600
Description: BCG vaccination with MicronJet600
Study NCT04064554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCG vaccination with conventional needle
Description: BCG vaccination with conventional needle
Study NCT01210235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLU-FIT Program
Description: In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
Study NCT03679013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Gabapentin and Intravenous Acetaminophen (IV APAP)
Description: Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.
Study NCT03679013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Opiate based pain regimen.
Description: Standard of care opiate based pain regimen.
Study NCT00113893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
Study NCT00113893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
Study NCT00113893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
Study NCT00113893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
Study NCT01966536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD133+ cells transplantation into ovarian artery of one ovary
Study NCT01948271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichuris Suis Ova
Description: During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
Study NCT02332330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEST
Study NCT01960205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5mg a day for 6 months
Study NCT01960205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: 2.5 mg a day for 6 months
Study NCT01960205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 500mg three times a day for 6 months
Study NCT01960205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention
Description: lifestyle intervention for 6 months
Study NCT00664677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terameprocol (EM-1421)
Description: Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
Study NCT02438774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: post-harvest intervention package
Description: The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
Study NCT02438774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine agriculture extension services
Description: This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
Study NCT02438774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine agriculture extension services
Description: This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
Study NCT05543421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: rTMS (30sessions) or iTBS (40sessions)
Study NCT05543421 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: rTMS (30sessions) or iTBS (40sessions)
Study NCT05543421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: rTMS (30sessions) or iTBS (40sessions)
Study NCT03501238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate Milk
Description: Chocolate bovine milk will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
Study NCT03501238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk substitute
Description: Chocolate milk substitute will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
Study NCT03501238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk substitute with gelatin
Description: Chocolate milk substitute with gelatin added will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
Study NCT04273503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring/educational session
Description: 12 mentoring/educational sessions focused on physical activity and healthy nutrition by Mayo Clinic experts.
Study NCT00003288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Study NCT01144221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramyocardial Cell therapy
Description: Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation
Study NCT01098357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone PDGF-BB Low dose
Description: BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
Study NCT01098357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone PDGF-BB High dose
Description: BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
Study NCT01098357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regranex
Description: Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
Study NCT01098357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone PDGF-BB Very Low Dose
Description: BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
Study NCT03058016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized recommendations for diet
Description: Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
Study NCT04579211 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urine lipoarabinomannan (LAM)
Description: Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
Study NCT03565588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education session with fixed incentive
Description: All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants assigned to receive fixed incentives will receive payment through mobile payments. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures.
Study NCT03565588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education session with lottery incentive
Description: All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants will participate in a lottery with prizes equivalent in expected value to the fixed incentives. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures.
Study NCT04505280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: Greater occipital nerve and cervical region injections once a week for 4 weeks
Study NCT04425278 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation with real current
Description: transcranial direct current stimulation with real current is a noninvasive technique to activate and modify the activity of the neurons
Study NCT04425278 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation with sham current
Description: transcranial direct current stimulation with sham current is a placebo
Study NCT01611077 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Candesartan cilexetil
Description: Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
Study NCT01843504 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
Study NCT01133327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.~The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire.
Study NCT01843504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
Study NCT02373163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
Study NCT02028221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
Study NCT02028221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
Study NCT00874276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Description: Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
Study NCT00874276 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Marker on Chromosome 14q24.3
Description: Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
Study NCT04883996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% EXP039
Description: 1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
Study NCT02373163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
Study NCT02373163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
Study NCT01611077 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan medoxomil
Description: Switch to olmesartan 40 mg tablets once daily for 42 days,
Study NCT01611077 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan/amlodipine
Description: then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
Study NCT04883996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline control
Description: Saline
Study NCT05913115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPA144
Description: FPA144 will be administered intravenously Q2W.
Study NCT01867658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Progel® Pleural Air Leak Sealant
Description: Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
Study NCT03641222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Traditional Chinese Medicine (TCM) Acupuncture
Study NCT03641222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Traditional Chinese Medicine (TCM) Acupuncture
Study NCT02374112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine supplementation
Study NCT02374112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation
Study NCT03007563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bilirubin concentration estimation from smartphone pictures
Description: pictures taken of the skin covering the breast bone
Study NCT03007563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilirubin concentration measured in standard blood samples
Study NCT03007563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bilirubin concentration measured by transcutaneous device
Study NCT00997191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
Study NCT01161524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 2 mg titrated up to 8-12 mg maximum; taken once daily.
Study NCT02716896 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation and chemoradiation
Description: Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
Study NCT02716896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical cystectomy
Description: Radical cystectomy will be performed on those who are randomized to this group.
Study NCT01727700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Once-daily, tablet
Study NCT01727700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04444427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLR2007
Description: Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
Study NCT05363943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double plating
Description: open reduction and internal fixation by using lateral and medial plates.
Study NCT05363943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal femoral replacement
Description: excision of the distal part of femur and replacement with distal femoral prosthesis
Study NCT04178083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: medical examination
Description: medical examination
Study NCT02640235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELSTAT
Study NCT01161524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo taken once daily.
Study NCT03078101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG [Jardiance]
Description: administered orally once daily
Study NCT02640235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel Original
Study NCT01066442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649 (Pitolisant)
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Study NCT00997191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone
Description: Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT>275um
Study NCT03078101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administered orally once daily
Study NCT00004184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 4B5 anti-idiotype vaccine
Study NCT00004184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim